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Repeats in toxinThe interaction of Bordetella pertussis adenylate cyclase toxin (CyaA) with complement receptor 3
(CR3, CD11b/CD18) involves N-linked oligosaccharide chains. To investigate the relative importance
of the individual N-glycans of CR3 for toxin activity, the asparagine residues of the consensus N-gly-
cosylation sites of CR3 were substituted with glutamine residues that cannot be glycosylated. Exam-
ination of CR3mutant variants andmass spectrometry analysis of the N-glycosylation pattern of CR3
revealed that N-glycans located in the C-terminal part of the CD11b subunit are involved in binding
and cytotoxic activity of CyaA. We suggest that these N-glycans form a deﬁned clustered saccharide
patch that enables multivalent contact of CR3 with CyaA, enhancing both afﬁnity and speciﬁcity of
the integrin–toxin interaction.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The secreted adenylate cyclase toxin (CyaA, ACT, or AC-Hly) is a
key virulence factor of Bordetella pertussis, the etiological agent of
whooping cough [1,2]. The toxin consists of a highly active N-ter-
minal adenylate cyclase (AC) enzyme and a pore-forming RTX
(Repeats in ToXin) hemolysin domain [3]. CyaA binds via the RTX
moiety to complement receptor 3 (CR3, CD11b/CD18, aMb2, or
Mac1) of myeloid phagocytes [4] and translocates into their cytosol
the catalytic AC domain, which upon binding of intracellular cal-
modulin causes unregulated increase of cAMP concentration [5].
This key signaling molecule then swiftly paralyzes bactericidal
functions of phagocytes [6].
CR3 used as receptor by CyaA belongs to the b2 family of leuko-
cyte integrins that mediate cell adhesion and signaling in immune
cells [7,8]. CR3 is a heavily glycosylated heterodimer prominently
expressed on monocytes, macrophages, polymorphonuclear leuko-
cytes, and natural killer cells. The CD11b subunit has 19 potential
N-glycosylation sites and the CD18 subunit harbors 6 such sites[9]. Structural studies have revealed that b2 integrins from human
leukocytes contain high mannose type, high molecular weight
complex type, and a small amount of hybrid-type oligosaccharide
chains [10]. However, it remains unknown which of the putative
N-glycosylation sites of the b2 integrins are modiﬁed with oligosac-
charide chains.
Glycosylation has been shown to be important for structure and
function of proteins since the early days of protein chemistry. The
importance of glycosylation is also indicated by the signiﬁcant per-
centage of genes in eukaryotic organisms that are devoted to gly-
cosylation functions. Despite large numbers of surface structures
in eukaryotes, also bacterial ﬁmbriae, pili and glycocalyx, or even
non-nucleated enveloped viruses, bear surface glycosylations
[11]. In the course of evolution, pathogens have learned to target
these sugars on cell surface/receptors to initiate infections. The
inﬂuenza virus hemagglutinin in early 1950s was shown to be
the ﬁrst microbial hemagglutinin to target sialic acid residues on
cell surface glycoconjugates [12]. Since then a number of viral, bac-
terial and protozoan pathogens have been shown to exploit cell
surface glycans to establish infection [13–15].
We have previously shown that the N-glycosylation of CR3 is
crucial for initial recognition of the integrin receptor by CyaA and
subsequent cytotoxic activities of the toxin [16]. To study the
effects of individual integrin saccharide chains on CyaA activities,
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CR3 were substituted here to glutamine residues that cannot be
modiﬁed by N-glycans. Using CR3 mutant variants and mass spec-
trometry analysis of the N-glycosylation pattern of CR3, we show
that the binding of CyaA to CR3 and its cytotoxicity toward cells
depends on multivalent protein–glycan interactions.
2. Materials and methods
2.1. Antibodies
Monoclonal antibodies (mAbs) MEM-174 and MEM-48 against
the human CD11b and CD18 subunits, respectively, were obtained
from Exbio, Vestec, Czech Republic. MAb OKM1 speciﬁc for human
CD11b was puriﬁed from the OKM1 hybridoma obtained from the
European Collection of Cell Cultures, Porton Down, UK. MAb M1/70
speciﬁc for murine and human CD11b was obtained from BD Bio-
sciences, San Jose, CA. MAbs were conjugated with Alexa Fluor
488 (AF488), ﬂuorescein isothiocyanate (FITC) or allophycocyanin
(APC), respectively.
2.2. Plasmids
pT7CACT1 was used for co-expression of cyaC and cyaA genes
allowing production of recombinant CyaC-activated CyaA in Esche-
richia coli [17]. pT7CACT1-derived plasmid was used for expression
of CyaA-AC toxoid that is unable to convert ATP to cAMP [17].
Human cDNAs encoding CD11b and CD18 were a kind gift of D.
Golenbock, Boston University School of Medicine, Boston, MA [18].
The cDNA for CD11b was cloned into the pcDNA3 expression vector
(Invitrogen, Carlsbad, CA) and the cDNA for CD18 into the
pcDNA3.1/Zeo (+) expression vector (Invitrogen, Carlsbad, CA). Oli-
gonucleotide-directed PCR mutagenesis was used to construct
pcDNA3-CD11b- and pcDNA3.1-CD18-derived plasmids for expres-
sion of CD11b and CD18 mutant variants harboring asparagine res-
idues of the consensus N-glycosylation sites of CR3 substituted
with glutamine residues.
2.3. Production, puriﬁcation and labeling of CyaA
CyaA and CyaA-ACwere produced in the E. coli strain XL1-Blue
(Stratagene, La Jolla, CA) and the proteins were puriﬁed by a com-
bination of ion exchange chromatography on DEAE-Sepharose and
hydrophobic chromatography on Phenyl-Sepharose [17]. On-col-
umn labeling of CyaA-AC was performed after the DEAE-Sephar-
ose puriﬁcation step. Protein samples were diluted 4-times in
ice-cold 50 mM Tris–HCl, pH 8.0 containing 1 M NaCl and loaded
on Phenyl-Sepharose beads. To label the CyaA-AC toxoid with
Dyomics 647 (Dy647), the Phenyl-Sepharose column was washed
with 50 mM sodium bicarbonate (pH 8.3) and the beads were sub-
sequently resuspended in the same buffer containing Dy647-NHS
ester (Dyomics, Jena, Germany) in a concentration to reach a
Dy647:protein molar ratio of 6:1. Labeling was performed at
25 C for 2 h, the column was washed with 50 mM Tris–HCl (pH
8.0) and labeled CyaA-AC was eluted in a buffer containing
50 mM Tris–HCl (pH 8) and 8 M urea. The molar ratio between
the ﬂuorescent dye and the protein was determined by spectro-
photometric analysis and found to be 4.8 moles Dy647 per mole
of CyaA-AC. The activities of labeled CyaA-AC were determined
as described elsewhere [17] and were comparable (>90%) to activ-
ities of unlabeled CyaA-AC.
2.4. Cells and growth conditions
The cells used in the experiments were CHO-K1 Chinese ham-
ster ovary cells (ATCC CCL 61) stably transfected with cDNAsencoding human CR3 or its mutant variants. The cells were grown
in F12K medium (GIBCO Invitrogen, Grand Island, N.Y.) supple-
mented with 10% fetal calf serum (FCS) (GIBCO Invitrogen, Grand
Island, N.Y.) and antibiotic antimycotic solution (ATB, 0.1 mg/ml
streptomycin, 1000 U/ml penicillin and 0.25 lg/ml amphotericin)
(Sigma–Aldrich, St. Louis, MO).
2.5. Establishment and selection of stably transfected cell lines
CHO cells were transfected with pcDNA3-CD11b and pcDNA3.1-
CD18 plasmids or their derivatives using Lipofectamine 2000
(Invitrogen, Grand Island, N.Y.) according to manufacturer’s
instructions. 48 h after transfection, medium supplemented with
600 lg/ml of G418 and 300 lg/ml of zeocin was added to cells to
select for stable transfectants. Stably transfected cells were stained
with anti-CD11b and anti-CD18 mAbs and single cells expressing
high levels of the integrin molecules were cloned using a FACS
Vantage cell sorter (Becton Dickinson, Franklin Lakes, NJ) by sort-
ing into individual wells of 96-well plates. After 3 weeks, the cells
from positive wells were expanded, stained with anti-CD11b and
anti-CD18 mAbs and CHO clones expressing on the cell surface
the same amounts of integrin molecules were identiﬁed by ﬂow
cytometry on a FACS LSR II instrument (BD Biosciences, San Jose,
CA) in the presence of Hoechst 33258. To monitor that the levels
of integrin expression on the cell surface of CHO clones remained
unchanged, the amounts of integrins were systematically quanti-
ﬁed in each experiment by staining with mAbs and subsequent
ﬂow cytometry analysis. When necessary, the obtained mean ﬂuo-
rescence intensity (MFI) values from mAbs were used to normalize
the relative values of CyaA binding.
2.6. MAb staining of the integrin molecules and CyaA binding to cells
For staining of integrin molecules on cell surface by mAbs,
2  105 stably transfected CHO cells were incubated for 30 min
at 4 C in 50 ll of HEPES-buffered salt solution (HBSS buffer;
10 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM KCl) complemented
with 2 mM CaCl2, 2 mM MgCl2, 1% (w/v) glucose and 1% (v/v) FCS
(cHBSS) containing saturating concentrations of different mAbs.
For CyaA binding assay, 2  105 cells were incubated in 100 ll of
cHBSS with Dy647-labeled CyaA-AC at a ﬁnal concentration of
2 lg/ml for 30 min at 4 C. After washing, cells were resuspended
in cHBSS and analyzed by ﬂow cytometry.
Data were analyzed using the FlowJo software (Tree Star, Ash-
land, OR) and appropriate gatings were used to exclude cell aggre-
gates and dead cells. Binding data were deduced from MFI values
and expressed as percentage of CyaA (mAb) binding to cells:
((MFI value of CyaA (mAb)-treated cells expressing the mutant
integrin molecule MFI value of CyaA (mAb)-treated mock trans-
fected CHO cells)/(an average of MFI values of CyaA (mAb)-treated
cells expressing CR3 MFI value of CyaA (mAb)-treated mock
transfected CHO cells))  100.
2.7. cAMP assay
1  105 transfected CHO cells were incubated with various con-
centrations of CyaA (1, 5, 10 and 20 ng/ml) for 30 min at 37 C in
200 ll of D-MEM and the reaction was stopped by addition of
0.2% Tween-20 in 50 mM HCl. Samples were boiled for 15 min at
100 C, neutralized by addition of 150 mM unbuffered imidazole
and cAMP levels were determined in cell lysates by competitive
ELISA, as described previously [19]. Intracellular concentrations
of cAMP were calculated at each toxin concentration in the linear
range of the dose–response curve and their mean values were
expressed as percentage of cAMP intoxication of CHO cells express-
ing the native form of CR3: ((c(cAMP) in cells expressing the
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(c(cAMP) in cells expressing CR3  c(cAMP) in mock transfected
CHO cells))  100.
2.8. Identiﬁcation of N-glycosylated asparagine residues of CR3 by
mass spectrometry
CR3 was puriﬁed from a crude membrane extract of CHO-
CD11b/CD18 cells. Brieﬂy, the scraped cells (5  108) were
washed with HBSS buffer and lyzed in hypotonic buffer (10 mM
HEPES, 2 mM CaCl2, pH 7.4) by multiple freeze-thaw cycles. The
crude membranes were collected at 50000 g for 30 min, resus-
pended in 10 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl2
and 20 mM n-dodecyl-b-D-maltoside (DDM; Applichem, Darms-
tadt, Germany), and incubated for 1 h at 4 C. Non-solubilized
material was spun down at 50000 g for 30 min and the superna-
tant was loaded onto an immunoafﬁnity column prepared by a
covalent linkage of MEM-174 mAb to a CNBr-activated Sepharose
4B (GE Healthcare, Piscataway, NJ). The column was extensively
washed with buffer containing 10 mM HEPES (pH 7.4), 150 mM
NaCl, 2 mM CaCl2, and 1 mM DDM before CD11b/CD18 heterodi-
mer was eluted by 10 mM sodium acetate (pH 3.5), 150 mM NaCl
and 1 mM DDM. The pH of the eluate was promptly adjusted to
pH 7.5 by addition of 3 M Tris–HCl (pH 8) and proteins were sep-
arated on 10% SDS polyacrylamide gel (SDS–PAGE). Coomassie
Brilliant Blue R-250 stained protein bands were cut off the gel
and decolorized two times in 50 mM 4-ethyl morpholine acetate
(pH 8.1)/50% acetonitrile (MeCN) for 15 min. Proteins were
reduced (100 mM TCEP, 5 min, 90 C), alkylated (50 mM iodoacet-
amide, 30 min, RT, dark) and digested by trypsin (10 ng/ll, 8 h,
40 C). Two bands of each protein were deglycosylated by PNGase
F and Endo H prior tryptic digestion. Tryptic peptides were
extracted from the gel using organic, acidic and basic extractionTable 1
Identiﬁcation of asparagine residues modiﬁed by N-glycans in the CD11b and CD18 subun
Integrin subunita Glycosidasea Peptideb
CD11b PNGase F ELF240DITNGAR
PNGase F STFI391DMTR
PNGase F AVF692DETK
PNGase F L734DFSLVGTPLSAFGNLRPVLAEDAQR
PNGase F EF801DVTVTVR
PNGase F T911DKTEFQLELPVK
PNGase F L940DFTASE946DTSR
PNGase F APVV1021DCSIAVCQR
PNGase F G1050DLSFDWYIK
Endo H LQVPVEAV86NMSLGLSLAATTSPPQLLACGP
Endo H STFI391NMTR(HexNAc)
Endo H L734NFSLVGTPLSAFGNLRPVLAEDAQR(Hex
Endo H EF801NVTVTVR(HexNAc)
Endo H STSCSINHPIFPENSEVTF880NITFDVDSK(Hex
Endo H A900NVTSENNMPR(HexNAc)
Endo H YL940NFTASE946NTSR(HexNAc2)
Endo H L978NQTVIWDRPQVTFSE993NLSSTCHTK(H
Endo H APVV1021NCSIAVCQR(HexNAc)
Endo H IQCDIPFFGIQEEF1044NATLK(HexNAc)
Endo H G1050NLSFDWYIK(HexNAc)
None STFI391NMTR(HexNAc2Hex8)
None L734NFSLVGTPLSAFGNLRPVLAEDAQR(Hex
None EF801NVTVTVR(HexNAc2Hex7)
None KAPVV1021NCSIAVCQR(HexNAc2Hex8)
CD18 PNGase F L50DFTGPGDPDSIR
PNGase F VTLYLRPGQAAAF116DVTFR
PNGase F LT212DNSNQFQTEVGK
PNGase F 642NCSAACPGLQLSNNPVK(HexNAc)
a CR3 was isolated from CHO cells transfected with the intact integrin molecule by imm
PAGE, isolated from the gel, treated with glycosidases PNGase F or Endo H, or buffer alo
b Positions of asparagine residues (bold), present in the putative N-glycosylation site
CD11b (GenBank accession number P11215) and CD18 (GenBank accession number P05
upon treatment with PNGase F to aspartic acid (bold). HexNAc, N-acetylhexosamine; Hprocedure, desalted on peptide micro trap cartridge (Michrom,
CA) and dried down on speed/vac (Thermo Fisher Scientiﬁc,
MA). Finally, they were dissolved in 1% TFA and 5% MeCN, applied
on capillary C18 analytical column (0.2  150 mm, 200A, 5 lm,
Michrom, CA) and eluted in water/acetonitrile gradient on Ulti-
mate 1000 HPLC system (LC Packings, NL). Gradient conditions
were as following: 0–1 min 0.1% formic acid 1% MeCN, 5 min
0.1% formic acid 5% MeCN, 30 min 0.1% formic acid 40% MeCN,
35 min 0.1% formic acid 95% MeCN, and 40 min 0.1% formic acid
95% MeCN. Capillary column was directly connected to the mass
analyzer. Mass spectrometric experiment was performed on a
commercial APEX-Qe FTMS instrument equipped with a 9.4 T
superconducting magnet and a Combi ESI/MALDI ion source (Bru-
ker Daltonics, Billerica MA). Mass spectra of the peptide samples
were obtained by accumulating ions in the collision hexapole and
running the quadrupole mass ﬁlter in non mass-selective (Rf-
only) mode so that ions of a broad m/z range (300–2000) were
passed to the FTMS analyzer cell. The accumulation time in colli-
sion cell was set at 0.5 s, the cell was opened for 1200 ls, 256
experiments were collected for one LC run where one experiment
consists of accumulation of six spectra. The instrument was exter-
nally calibrated using triply and double charged ions of angioten-
sin I. It results in typical internal mass accuracy below 1 ppm.
After the analysis the spectra were apodized and processed using
sin apodization and data reducing macro, respectively. The list of
unique monoisotopic masses was generated for each sample and
data interpretation was performed by MS Links algorithm. Only
assignment below 2 ppm was considered as positive hit.
2.9. Statistical analysis
Results were expressed as arithmetic mean ± S.D. and statistical
differences were examined by Student’s t test.its of CR3 by peptide mass mapping.
Experimental mass [M+H]+ Error [ppm]
1134.5883 1.6
970.4655 1.3
809.4032 1.5
2786.4781 1.9
1065.5560 1.8
1547.8298 1.4
1404.6255 1.6
1474.7124 1.5
1243.5975 1.9
TVHQTCSENTYVK(HexNAc) 4785.3807 0.3
1172.5607 1.1
NAc) 2988.5767 0.9
1267.6530 0.3
NAc) 3388.5530 0.1
1435.6461 1.5
1808.8181 0.4
exNAc) 3164.5266 1.9
1676.8076 1.5
2473.1943 0.7
1445.6933 1.9
2672.0630 0.2
NAc2Hex6) 4163.9692 1.4
2605.1025 0.2
3304.4019 1.4
1389.6630 1.1
2025.0897 1.1
1580.7527 1.8
2032.9397 1.7
unoafﬁnity chromatography, the CD11b and CD18 subunits were separated by SDS–
ne, digested by trypsin and analyzed by high resolution mass spectrometry.
s (underlined) of CR3 are numbered according to the primary sequence of human
107). N-glycosylated asparagine residues of both CD11b and CD18 were converted
ex, hexose.
Fig. 1. Interaction of CyaA with CR3 involves multivalent oligosaccharide chain binding. The 19 conserved asparagine residues of CD11b and 6 asparagine residues of CD18
were each individually replaced by a glutamine residue and the mutant integrin variants were stably expressed on surface of CHO cells. 2  105 cells were incubated with
enzymatically inactive CyaA-AC-Dy647 at a ﬁnal concentration of 2 lg/ml for 30 min at 4 C and the cells were analyzed by ﬂow cytometry. (A) Overlay histograms from one
representative binding experiment. CyaA-AC (left panel), anti-CD11b mAb (central panel) and anti-CD18 mAb (right panel) binding to mock-, CD11b/CD18- and
CD11bN1075Q/CD18-transfected CHO cells was analyzed, respectively, by determination of relative ﬂuorescence intensity (RFI). (B and C) CyaA-AC binding data for
transfected cells expressing (B) CD11b or (C) CD18 mutant variants were deduced from the mean ﬂuorescence intensities and expressed as percentage of CyaA-AC binding to
CHO-CD11b/CD18 cells (mean ± S.D.; nP 8; ⁄P < 0.005).
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3.1. Human CR3 is glycosylated at the majority of predicted N-
glycosylation sites
To analyze which of the predicted canonical N-glycosylation
sites (Asn-Xaa-Ser/Thr) of CR3 are truly modiﬁed with N-linked oli-
gosaccharide chains, the integrin molecule was isolated from CHO
cells expressing intact CR3 by immunoafﬁnity chromatography
using anti-CD11b mAb (MEM-174) coupled to agarose beads. The
CD11b and CD18 subunits were separated by SDS–PAGE, isolated
from the gel, treated with glycosidases PNGase F or Endo H, or buf-
fer alone, proteolytically digested and analyzed by high resolution
mass spectrometry. The sequence coverage was 55%/53%, 75%/55%
and 56%/26% for buffer, Endo H and PNGase F treated CD11b/CD18,
respectively (data not shown). As shown in Table 1, the mass spec-
trometry analysis detected 15 and 4 asparagine residues modiﬁed
with N-linked oligosaccharide chains in CD11b and CD18, respec-
tively. Since the signal for other potential glycopeptides of CR3
was missing due to the low sample amount, it cannot be excluded
that the remaining 6 putative N-glycosylation sites of CR3 were
also modiﬁed with oligosaccharide chains. Therefore, all putative
N-glycosylation sites of CR3 were mutagenized to examine therelative importance of individual N-glycans of the integrin for
binding and biological activity of CyaA.
3.2. Mutation of seven N-glycosylation sites in CR3 results in reduced
binding of CyaA
The asparagine residue of each of the canonical N-glycosylation
sites of CR3 was substituted to a glutamine residue that cannot be
glycosylated. Plasmid constructs for expression of CD11b mutant
variants were transfected to CHO cells expressing the intact
CD18 subunit, and plasmid constructs encoding CD18 mutant vari-
ants were transfected to CHO cells producing intact CD11b. CHO
transfectants with stable expression of CR3 variants were selected
by single-cell sorting and expression of the mutant integrins on the
surface of transfected CHO cells was conﬁrmed with speciﬁc anti-
CD11b and anti-CD18 mAbs by ﬂow cytometry. Both CD11b and
CD18 were detected in all 25 mutants, suggesting that no particu-
lar individual N-linked oligosaccharide chain was indispensable for
surface expression of CR3 (data not shown). The capacity of CR3
mutants to bind CyaA was assessed by ﬂow cytometry (a represen-
tative binding experiment is shown in Fig. 1A). As shown in Fig. 1B
and C, transfected cells expressing most mutant integrin variants
bound CyaA with similar efﬁcacy as cells expressing intact CR3.
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Fig. 2. Structures of CD11b crucial for CyaA binding are not altered by single
residue substitutions of CR3. Transfected CHO cells expressing mutant integrin
molecules with reduced capacity to bind CyaA were treated with various CD11b-
speciﬁc mAbs recognizing the same segments as CyaA (Osicka et al., unpublished
results) for 30 min at 4 C and the cells were analyzed by ﬂow cytometry. Antibody
binding was expressed as percentage of mAb binding to CHO cells expressing the
native form of CD11b/CD18 (mean ± S.D.; nP 8).
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Fig. 3. Cells expressing CR3 mutant variants with reduced capacity to bind CyaA are
less susceptible to intoxication by cAMP upon incubation with the toxin. Transfec-
ted cells expressing CR3 mutants with reduced capacity to bind CyaA were
incubated with various concentrations of the toxin for 30 min at 37 C and the
amounts of accumulated cAMP were determined in cell lysates by competitive
ELISA, as described previously [19]. Intracellular concentrations of cAMP were
calculated at each toxin concentration in the linear range of the dose–response
curve and their mean values were expressed as percentage of cAMP intoxication of
CHO cells expressing the native form of CD11b/CD18 (mean ± S.D.; n = 6; ⁄P < 0.05).
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positions 469, 692, 801, 900, 978, 1021 and 1075 of the CD11b sub-
unit each individually reduced binding of CyaA by about 8–44%
(statistically signiﬁcant, Fig. 1B). As shown in Fig. 2, this reduction
of CyaA binding was not due to an alteration of the structure or a
decreased expression of the mutant integrins, since three different
CD11b-speciﬁc mAbs recognizing the same segments as CyaA (Osi-
cka et al., unpublished results) bound the CR3 mutant variants
with the same efﬁcacy as the intact CR3.CHO cells expressing CR3 mutant variants with signiﬁcantly
reduced CyaA binding capacity were further analyzed for their sus-
ceptibility to intoxication by cAMP upon incubation with the toxin.
In comparison with CHO cells expressing intact CR3, intracellular
cAMP levels in cells expressing mutant integrins with substitutions
at positions 469, 801, 978 and 1075 of CD11b were reproducibly
reduced by about 30–38% after treatment with CyaA (Fig. 3).
CHO cells expressing CR3 mutant variants with substitutions at
positions 692, 900 and 1021 were also less intoxicated by the toxin
than the cells expressing the intact integrin, but the decrease was
not statistically signiﬁcant (Fig. 3). All these data demonstrate that
the initial interaction between CyaA and its integrin receptor
depends on recognition of multiple oligosaccharide chains local-
ized in the C-terminal part of the CD11b subunit by the toxin. This
multivalent contact of CR3 with CyaA then might increase both
afﬁnity and speciﬁcity of the integrin–toxin interaction.4. Discussion
Bacterial lectins can be broadly classiﬁed into adhesins and tox-
ins, both of which are known to exploit host cell surface glycans to
attach, mediate toxicity and facilitate infection. Bacterial lectins
are known to bind membrane glycolipids, and few bind also cell
surface glycoproteins [20]. For example, cholera toxin of Vibrio
cholerae is a well-studied example of a bacterial toxin exploiting
host monosialoganglioside GM1 for attachment and invasion
[21], subtilase cytotoxin of Shiga-toxigenic E. coli recognizes N-gly-
cosylated integrin a2b1 [22], and the B subunit of pertussis toxin of
B. pertussis has lectin like activity toward a 165-kilodalton cell sur-
face glycoprotein [23]. In addition, we previously demonstrated
that biological activities of RTX cytotoxins depend on the recogni-
tion of N-linked oligosaccharides of their respective b2 integrin
receptors [16]. Here we used the RTX protein CyaA and b2 integrin
CR3 variants, harboring the asparagine residue of each of the con-
sensus N-glycosylation sites of CR3 substituted with a glutamine
residue. We show that seven different N-glycosylation sites of
CR3, some of them conﬁrmed to be modiﬁed with N-linked oligo-
saccharide chains by mass spectrometry, were involved in binding
and cytotoxic activity of CyaA. Interestingly, all these N-glycosyla-
tion sites were located in the C-terminal part of the CD11b subunit,
demonstrating that the oligosaccharide chains important for initial
recognition of the toxin are not randomly distributed in the inte-
grin heterodimer. This corresponds well with our recent data
showing that CyaA binding to CR3 also depends on the recognition
of a proteinaceous segment (residues 614–682) localized in the
same portion of CD11b (Osicka et al., unpublished data) and close
to glycosylated asparagine residue 692.
Many glycan-binding proteins bind to their glycan partners via
a multivalent interaction. In such case several glycan moieties of
the receptor participate to mediate individual binding interaction
of low afﬁnity with the glycan binding protein (Kd value in the
micromolar range), but ultimately having a high avidity due to
multivalency of the interaction, which is relevant in vivo [20,24].
The complete loss of CyaA binding observed in the absence of
CR3 glycosylation [16] and the partial reduction in the toxin bind-
ing observed here in case of some of the CR3 mutant variants indi-
cate that CyaA uses some of the glycan chains as active binding
partners in a multivalent binding interaction with the integrin.
This multivalent binding then helps CyaA to achieve a low Kd value
in the nanomolar range [4] and hence to act as a potent toxin
in vivo. Similar lowering of the Kd value due to multivalent glycan
mediated avidity has been previously shown for cholera toxin [25].
The b2 integrins are known to exist in three distinct conforma-
tions; the compact bent conformation, the intermediate conforma-
tion, and the open conformation [26,27]. Each step of unfolding or
S. Hasan et al. / FEBS Letters 589 (2015) 374–379 379folding of the integrin will have a direct impact on the spatial
arrangement of the associated glycan chains. We hypothesize that
the bent conformation of CR3, which has been shown to be prefer-
entially recognized by CyaA (Osicka et al., unpublished data), could
lead to the close packing of the oligosaccharide chains and presen-
tation of a novel epitope, termed as a clustered saccharide patch.
This higher level of glycan organization was described previously
and may also involve the peptide backbone as a binding partner
in interaction with the glycan binding protein in order to enhance
the afﬁnity and speciﬁcity [24,28]. Indeed, the contribution of the
segment between residues 614–682 of CD11b was recently shown
to be crucial for CyaA binding and its cytotoxic activities (Osicka
et al., unpublished data). Thus, the oligosaccharide chains and
the residue 614–682 proteinaceous segment of CD11b may
together form a highly organized structure, which could be respon-
sible for high afﬁnity binding of CyaA and its subsequent biological
activities. As we demonstrated here, the CyaA-binding site can be
destabilized by the removal of some of the individual oligosaccha-
ride chains, resulting in reduced CyaA binding and cAMP intoxica-
tion of target cells. The conformation of the complex CyaA-binding
site can be also altered at each level of glycosylation of CR3, from
the chitobiose core to the terminal sialic acid residues, as described
previously [16]. The removal of terminal sialic acid residues
reduced the toxin binding to a mere 20% and the further removal
of trimanosyl and chitobiose cores reduced the binding even fur-
ther, suggesting that each level of glycosylation has a contribution
(even minor) to the formation of the correctly structured CyaA-
binding site. Similarly, almost complete loss of CyaA binding and
cytotoxic activity was observed when the residue 614–682 seg-
ment of CD11b forming the CyaA-binding site was replaced with
a highly homologous sequence of CD11c, which does not bind
CyaA, or when point substitutions were introduced into this seg-
ment (Osicka et al., unpublished data). Taken together, all these
results suggest that some of the N-glycans and the residue 614–
682 segment, all located in the C-terminal part of CD11b, form a
highly complex CyaA-binding site, the structural integrity of which
is essential for high-afﬁnity interaction between CyaA and its CR3
receptor.
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